Odyssey Therapeutics Inc. Common Stock
Financials
Valuation Metrics
Odyssey Therapeutics Inc. Common Stock's Market Cap is $1.18B. Ranked #2403 of 3,118 in US market (top 77%), #975 of 1,460 on NASDAQ (top 67%) by Market Cap.
Investment Metrics(as of 2026-09-11)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.18B | US#2,403/3,118 |
| Revenue | $3M | US#2,862/3,118 |
| Net Income | $-149M | US—/3,118 |
| Total Assets | $270M | US#2,941/3,118 |
| Net Assets | $-488M | US#3,023/3,118 |
| Employees | 100 | US#2,634/3,118 |
| Value | ||
| P/S | 397.74x | US#2,978/3,118 |
| FCF Yield | -11.04% | US—/3,118 |
| Profitability | ||
| ROA | -55.10% | US#3,008/3,118 |
| Op. Margin | -5415.19% | US#2,863/3,118 |
| Financial Health | ||
| Total Debt | $27M | US#2,718/3,118 |
| FCF | $-131M | US#2,692/3,118 |
| Cash | $42M | US#2,657/3,118 |
| Current Ratio | 7.20x | US#350/3,118 |
| Performance | ||
| 1M Return | 14.13% | US#134/3,118 |
| From 52W High | -15.22% | US#1,422/3,118 |
| 1Y MDD | -18.41% | US#588/3,118 |
| Trading | ||
| Volume | 195,005 shares | US#2,622/3,118 |
| Trading Value | $5M | US#2,663/3,118 |
| Per Share | ||
| EPS | $-3.09 | US—/3,118 |
| BPS | $-10.16 | US—/3,118 |
Company Info
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.